Lexaria Bioscience (LEXX) has been granted two new patents from the United States Patent and Trademark Office for the use of DehydraTECH enhanced processing technology related to the treatment of epilepsy. Lexaria has received its 5th and 6th US patents granted in its patent family #24, Compositions and Methods for Treating Epilepsy. These patents complement earlier research which indicated that DehydraTECH-CBD was capable of mitigating epileptic seizures in rodents, and was also absorbed into the bloodstream more effectively than the commercially available cannabinoid-based anti-seizure medication, Epidiolex. The new patents expire in 2043, if not extended, and increase Lexaria’s granted patent total to 48.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEXX:
- Lexaria Initiates Groundbreaking Biodistribution Study for DehydraTECH GLP-1
- Lexaria begins biodistribution study for DehydraTECH GLP-1
- Lexaria Advances Human Study on Diabetes and Weight Loss Treatment
- Lexaria Bioscience provides update on ongoing human study GLP-1-H24-4
- Lexaria Bioscience Strengthens GLP-1 Drug Delivery Focus and Expands Patent Portfolio in 2024